Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide - PubMed (original) (raw)
Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide
M Frangione-Beebe et al. Vaccine. 2000.
Erratum in
- Vaccine 2001 Jul 16;19(28-29):4087
Abstract
The ability of a peptide vaccine derived from the human T-lymphotropic virus type 1 (HTLV-1) surface envelope glycoprotein protein (gp46) to mimic the native protein and elicit a protective immune response has been examined. This peptide construct, designated MVFMF2, comprises amino acids (aa) 175-218 of gp46 linked by a four residue turn (GPSL) to a promiscuous T-cell epitope from the measles virus fusion protein (MVF, aa 288-302). The peptide was structurally characterized by circular dichroism (CD) spectroscopy and was found to contain alpha-helical secondary structure. The immunogenicity of MVFMF2 in rabbits and mice was evaluated by direct ELISA and competitive ELISA using peptide constructs and the recombinant protein ACH-RE3 (aa 165-306). This peptide, when administered with adjuvant (N-acetyl-glucosamine-3yl-acetyl-L-alanyl-D-isoglutamine, nor-MDP) was immunogenic in an outbred population of both rabbits and mice. Furthermore, the peptide construct was encapsulated in biodegradable microspheres of poly(D,L-lactide-co-glycolide) to eliminate booster immunization and to examine adjuvant requirements. The data indicate that MVFMF2 shows enhanced immunogenicity when encapsulated in biodegradable microspheres. Inoculation of the encapsulated peptide produced a similar humoral response to that of the free peptide, but did not require the use of adjuvant. Elicited anti-rabbit and anti-mouse antibodies recognized whole viral preparations and the recombinant protein ACH-RE3 in ELISA assays. Additionally, inoculated rabbits exhibited enhanced reactivity to viral antigens by western blot compared to non-vaccinated controls. Although anti-rabbit and anti-mouse antibodies were capable of inhibiting syncytium formation at low dilutions, rabbits were not protected from cell-associated viral challenge. Future development of vaccines to HTLV-1 may need to incorporate the ability to elicit cell-mediated immune responses in order to protect against cell-associated viral infection.
Similar articles
- Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
Lairmore MD, DiGeorge AM, Conrad SF, Trevino AV, Lal RB, Kaumaya PT. Lairmore MD, et al. J Virol. 1995 Oct;69(10):6077-89. doi: 10.1128/JVI.69.10.6077-6089.1995. J Virol. 1995. PMID: 7545241 Free PMC article. - Microencapsulation of a synthetic peptide epitope for HTLV-1 in biodegradable poly(D,L-lactide-co-glycolide) microspheres using a novel encapsulation technique.
Frangione-Beebe M, Rose RT, Kaumaya PT, Schwendeman SP. Frangione-Beebe M, et al. J Microencapsul. 2001 Sep-Oct;18(5):663-77. doi: 10.1080/02652040110055216. J Microencapsul. 2001. PMID: 11508771 - Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
Conrad SF, Byeon IJ, DiGeorge AM, Lairmore MD, Tsai MD, Kaumaya PT. Conrad SF, et al. Biomed Pept Proteins Nucleic Acids. 1995;1(2):83-92. Biomed Pept Proteins Nucleic Acids. 1995. PMID: 9346859 - Evaluation of immunodominant epitopes of human T-lymphotropic virus type 1 (HTLV-I) using synthetic peptides.
Lairmore MD, Lal RB, Kaumaya PT. Lairmore MD, et al. Biomed Pept Proteins Nucleic Acids. 1995;1(3):117-22. Biomed Pept Proteins Nucleic Acids. 1995. PMID: 9346842 Review. - Advances in HTLV-1 peptide vaccines and therapeutics.
Lynch MP, Kaumaya PT. Lynch MP, et al. Curr Protein Pept Sci. 2006 Apr;7(2):137-45. doi: 10.2174/138920306776359803. Curr Protein Pept Sci. 2006. PMID: 16611139 Review.
Cited by
- HTLV-1 vaccination Landscape: Current developments and challenges.
Letafati A, Bahari M, Salahi Ardekani O, Nayerain Jazi N, Nikzad A, Norouzi F, Mahdavi B, Aboofazeli A, Mozhgani SH. Letafati A, et al. Vaccine X. 2024 Jul 16;19:100525. doi: 10.1016/j.jvacx.2024.100525. eCollection 2024 Aug. Vaccine X. 2024. PMID: 39105133 Free PMC article. Review. - An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.
Tu JJ, King E, Maksimova V, Smith S, Macias R, Cheng X, Vegesna T, Yu L, Ratner L, Green PL, Niewiesk S, Richner JM, Panfil AR. Tu JJ, et al. J Virol. 2024 Feb 20;98(2):e0162323. doi: 10.1128/jvi.01623-23. Epub 2024 Jan 9. J Virol. 2024. PMID: 38193692 Free PMC article. - Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies.
Seighali N, Shafiee A, Rafiee MA, Aminzade D, Mozhgani SH. Seighali N, et al. BMC Infect Dis. 2023 May 11;23(1):320. doi: 10.1186/s12879-023-08289-7. BMC Infect Dis. 2023. PMID: 37170214 Free PMC article. - Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years.
Santana CS, Andrade FO, da Silva GCS, Nascimento JOS, Campos RF, Giovanetti M, Santos LA, Gois LL, Alcantara LCJ, Barreto FK. Santana CS, et al. Front Immunol. 2023 Feb 13;14:1073779. doi: 10.3389/fimmu.2023.1073779. eCollection 2023. Front Immunol. 2023. PMID: 36860854 Free PMC article. - The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine.
Tu JJ, Maksimova V, Ratner L, Panfil AR. Tu JJ, et al. Front Microbiol. 2022 May 4;13:897346. doi: 10.3389/fmicb.2022.897346. eCollection 2022. Front Microbiol. 2022. PMID: 35602078 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases